Skip to search formSkip to main contentSkip to account menu

UK-427,857

Known as: UK 427,857, UK-427857 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

maraviroc

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Probing the limits of C–H functionalization methods in the complex synthetic contexts of the indoxamycins and maraviroc (UK-427,857)
............................................................................................. iii Dedication… 
Review
2014
Review
2014
Long-term Maraviroc Therapy and Limited Side Effects in an HIV-1 Experienced Patient: Six Years of Antiretroviral Observation.
Maraviroc, originally designated UK-427857, is a small molecule and the first oral antiretroviral drug in the CCR5 receptor… 
2010
2010
An LC-MS-MS method for quantitative determination of maraviroc (UK-427,857) in human plasma, urine and cerebrospinal fluid.
Maraviroc is a first-in-class CCR5 antagonist that shows potent anti-HIV-1 activity in vitro and in vivo and is well tolerated in… 
Review
2008
Review
2008
Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection
Background: Maraviroc is the only approved CCR5 coreceptor antagonist on the market for treatment of HIV-1 infection. It uses a… 
Review
2008
Review
2008
Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection.
BACKGROUND Maraviroc is the only approved CCR5 coreceptor antagonist on the market for treatment of HIV-1 infection. It uses a… 
2005
2005
The Discovery and Exploratory Development of Maraviroc (UK-427,857): A Novel CCR5 Antagonist for the Treatment of HIV
Maraviroc is a novel CCR5 antagonist and is the most advanced clinical candidate in Pfizer's CCR5 discovery and development… 
2005
2005
Human Immunodeficiency Virus (HIV) Entry Inhibitors (CCR5 Specific Blockers) in Development: Are They the Next Novel Therapies?
Abstract Since the introduction of the nucleoside reverse transcriptase inhibitor zidovudine in 1987, the number of the available… 
Review
2004
Review
2004
New advances in HIV entry inhibitors development.
Considerable advances have been made in the last years in the design of derivatives acting as inhibitors of HIV entry and fusion… 
2004
2004
5th Antiviral Drug Discovery and Development Summit.
The 5th Antiviral Drug Discovery and Development Summit provided an up-to-date snapshot of the ongoing developments in the area… 
2003
2003
Gateways to clinical trials. March 2003.
Gateways to clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)